As published on-line via The ASCO Post on January 30, 2019, "Effectiveness of EsophaCap Tool in the Diagnosis of Barrett’s Esophagus", we share the following highlights:
We expect to penetrate and convert a substantial portion of endoscopic market currently used for screening patients who have GERDs (est. 30 million in USA.) and other upper GI conditions (est. 50 Million is USA). The second huge market is that of diagnosis of Helicobacter pylori (H. pylori) a Gram‐negative, microaerophilic bacterium found in the stomach. H.pylori is commonly present in patients with chronic gastritis and gastric ulcers. It is also linked to the development of duodenal ulcers and stomach cancer. More than 50% of the world's population harbor H. pylori in their upper gastrointestinal tract. Physicians must be able to diagnose H.pylori in order to prescribe the proper medications.
Medical Cost Savings: The average endoscopic procedure costs $2700 in the USA. Our product together with the Biomarker test kits is a low cost, quick and easy alternative and we hope to have its use become as routine as Pap-smears are today.
The FDA cleared swallow-able screening device is comprised of a medical grade foam ball that is compressed into a swallowable capsule which is deployed and withdrawn orally within 10 minutes. This is a Doctors Office and/or possible home use procedure that will serve to pre-screen patients when used together with our clients Biomarker Test Kits.
The three major cancer research partner/clients based in USA, Canada and in the UK have already begun advanced human clinical trials using the EsophaCaps with their unique Genetic, Epigenetic, and protein based rapid diagnosis kits. Several other distinquished cancer research institutions are currently applying for research grants to explore the use of the EsophaCap™ with their kits.
With the recent developments in Genome Sequencing, several corporations and medical institutions have developed Biomarker Test Kits to detect diseases of the esophagus without requiring the use of invasive and uncomfortable endoscopic techniques. The problem is that they do not have efficient non-endoscopic (non-invasive) methods of obtaining cellular specimens from patents.
Our initial focus will target Barrett's esophagus which is a disorder in which the lining of the esophagus is damaged by stomach acid and changed to a lining similar to that of the stomach.
Patients with Barrett's esophagus may develop more changes in the esophagus called dysplasia. When dysplasia is present, the risk of getting cancer of the esophagus increases. Early detection and treatment is highly desirable as this is a potentially lethal malignancy.
FDA cleared device for early detection of Barrett’s Esophagus and other Upper GI diseases such as cancer and H-pylori.
The EsophaCap® is an FDA 510k cleared Non-endoscopic swallowable screening device for esophageal bottle-brush cellular retrieval for use with new Genome Sequencing diagnostic tests (Biomarkers) that are expected to become mass "out-patient" screening tests used for the early detection of Barrett’s Esophagus and other diseases